RVTY Revvity
Q3 2025 10-Q
Revvity (RVTY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Revenue $698.9M for Q3 FY25, up 2% YoY from $684.0M; Life Sciences up 1% to $342.8M, Diagnostics up 3% to $356.1M
- • Gross margin 53.6% for Q3 FY25, down 2.66 pts YoY from 56.3%, cost of revenue 46.4% vs 43.7% YoY due to tariffs and FX impact
Risk Factors
- • New risk: Increased customer spending caution due to recent U.S. funding and regulatory uncertainties undermining purchase timing and volumes
- • Updated risk: More costly or less effective risk mitigation due to recent market developments affecting hedging and insurance strategies
Quarterly Financial SummaryXBRL
Revenue
$699M
Net Income
$47M
Net Margin
6.7%
Source: XBRL data from Revvity Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Revvity Quarterly Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.